Expanded Access Program for RP in Adults

Summary

This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications